Ligand-based design of a potent and selective inhibitor of cytochrome P450 2C19

Journal of Medicinal Chemistry

Volumn 55, Issue 3, 2012, Pages 1205-1214

  Foti, Robert S ^a   Rock, Dan A ^a   Han, Xiaogang ^b   Flowers, Robert A ^c   Wienkers, Larry C ^a   Wahlstrom, Jan L ^a  

^a AMGEN INC   (United States)

^b PFIZER INC   (United States)

^c LEHIGH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; CYTOCHROME P450 2C19 INHIBITOR; CYTOCHROME P450 INHIBITOR; OMEPRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; DRUG DESIGN; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STABILITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; LIVER MICROSOME; PHARMACOPHORE; STRUCTURE ACTIVITY RELATION;

ARYL HYDROCARBON HYDROXYLASES; CATALYTIC DOMAIN; DRUG DESIGN; HUMANS; HYDROXYLATION; LIGANDS; MEPHENYTOIN; MICROSOMES, LIVER; MODELS, MOLECULAR; OMEPRAZOLE; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84856937028     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm201346g     Document Type: Article

References (44)

1. Ortiz de Montellano, P. R.; De Voss, J. J. Substrate Oxidation by Cytochrome P450 Enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed.; Ortiz de Montellano, P. R., Ed.; Kluwer Academic/Plenum Publishers: New York, 2005; pp 183-245.
2. Guengerich, F. P. Human Cytochrome P450 Enzymes. In Cytochrome P450: Structure, Mechanism, and Biochemistry, 3rd ed.; Ortiz de Montellano, P. R., Ed.; Kluwer Academic/Plenum Publishers: New York, 2005; pp 377-530.
3. Guengerich, F. P.; MacDonald, J. S. Applying mechanisms of chemical toxicity to predict drug safety Chem. Res. Toxicol. 2007, 20, 344-369 (Pubitemid 46548682)
4. Denton, T. T.; Zhang, X.; Cashman, J. R. 5-Substituted, 6-Substituted, and Unsubstituted 3-Heteroaromatic Pyridine Analogues of Nicotine as Selective Inhibitors of Cytochrome P-450 2A6 J. Med. Chem. 2004, 48, 224-239 (Pubitemid 40105261)
5. Gomaa, M. S.; Bridgens, C. E.; Aboraia, A. S.; Veal, G. J.; Redfern, C. P.; Brancale, A.; Armstrong, J. L.; Simons, C. Small Molecule Inhibitors of Retinoic Acid 4-Hydroxylase (CYP26): Synthesis and Biological Evaluation of Imidazole Methyl 3-(4-(Aryl-2-ylamino)phenyl)propanoates J. Med. Chem. 2011, 54, 6803-6811
6. Kim, S.; Ko, H.; Park, J. E.; Jung, S.; Lee, S. K.; Chun, Y.-J. Design, Synthesis, and Discovery of Novel trans -Stilbene Analogues as Potent and Selective Human Cytochrome P450 1B1 Inhibitors J. Med. Chem. 2001, 45, 160-164 (Pubitemid 34038551)
7. Paine, M. F.; Hart, H. L.; Ludington, S. S.; Haining, R. L.; Rettie, A. E.; Zeldin, D. C. The human intestinal cytochrome P450 "pie" Drug Metab. Dispos. 2006, 34, 880-886
8. Ring, B. J.; Eckstein, J. A.; Gillespie, J. S.; Binkley, S. N.; VandenBranden, M.; Wrighton, S. A. Identification of the human cytochromes p450 responsible for in vitro formation of R-and S -norfluoxetine J. Pharmacol. Exp. Ther. 2001, 297, 1044-1050 (Pubitemid 32472502)
9. Feng, H. J.; Huang, S. L.; Wang, W.; Zhou, H. H. The induction effect of rifampicin on activity of mephenytoin 4′-hydroxylase related to M1 mutation of CYP2C19 and gene dose Br. J. Clin. Pharmacol. 1998, 45, 27-29 (Pubitemid 28062850)
10. Raucy, J. L.; Mueller, L.; Duan, K.; Allen, S. W.; Strom, S.; Lasker, J. M. Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes J. Pharmacol. Exp. Ther. 2002, 302, 475-482 (Pubitemid 34787209)
11. Foti, R. S.; Wahlstrom, J. L. CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles Drug Metab. Dispos. 2008, 36, 523-528 (Pubitemid 351397977)
12. Wang, J. H.; Li, P. Q.; Fu, Q. Y.; Li, Q. X.; Cai, W. W. Cyp2c19 genotype and omeprazole hydroxylation phenotype in Chinese Li population Clin. Exp. Pharmacol. Physiol. 2007, 34, 421-424
13. Holt, S.; Howden, C. W. Omeprazole. Overview and opinion Digestive Dis. Sci. 1991, 36, 385-393
14. Howden, C. W. Clinical pharmacology of omeprazole Clin. Pharm. 1991, 20, 38-49
15. Spencer, C. M.; Faulds, D. Lansoprazole. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders Drugs 1994, 48, 404-430
16. Meyer, U. A. Metabolic interactions of the proton-pump inhibitors lansoprazole, omeprazole and pantoprazole with other drugs Eur. J. Gastroenterol. Hepatol. 1996, 8 (Suppl 1) S21-S25
17. Meyer, U. A. Interaction of proton pump inhibitors with cytochromes P450: consequences for drug interactions Yale J. biol. Med. 1996, 69, 203-209 (Pubitemid 27209693)
18. Ko, J. W.; Sukhova, N.; Thacker, D.; Chen, P.; Flockhart, D. A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms Drug Metab. Dispos. 1997, 25, 853-862 (Pubitemid 27318604)
19. Andersson, T.; Andren, K.; Cederberg, C.; Edvardsson, G.; Heggelund, A.; Lundborg, P. Effect of omeprazole and cimetidine on plasma diazepam levels Eur. J. Clin. Pharmacol. 1990, 39, 51-54 (Pubitemid 20216511)
20. Andersson, T.; Cederberg, C.; Edvardsson, G.; Heggelund, A.; Lundborg, P. Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole Clin. Pharmacol. Ther. 1990, 47, 79-85 (Pubitemid 20041214)
21. Enderle, C.; Muller, W.; Grass, U. Drug interaction: omeprazole and phenprocoumon BMC Gastroenterol. 2001, 1, 2
22. Pearson, J.; Dahal, U. P.; Rock, D.; Peng, C. C.; Schenk, J. O.; Joswig-Jones, C.; Jones, J. P. The kinetic mechanism for cytochrome P450 metabolism of type II binding compounds: evidence supporting direct reduction Arch. Biochem. Biophys. 2011, 511, 69-79
23. Peng, C. C.; Pearson, J. T.; Rock, D. A.; Joswig-Jones, C. A.; Jones, J. P. The effects of type II binding on metabolic stability and binding affinity in cytochrome P450 CYP3A4 Arch. Biochem. Biophys. 2010, 497, 68-81
24. Chiba, M.; Jin, L.; Neway, W.; Vacca, J. P.; Tata, J. R.; Chapman, K.; Lin, J. H. P450 interaction with HIV protease inhibitors: relationship between metabolic stability, inhibitory potency, and P450 binding spectra Drug Metab. Dispos. 2001, 29, 1-3 (Pubitemid 32041672)
25. Li, H.; Sun, J.; Fan, X.; Sui, X.; Zhang, L.; Wang, Y.; He, Z. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction J. Comput.-Aided Mol. Des. 2008, 22, 843-855
26. Locuson, C. W., II; Suzuki, H.; Rettie, A. E.; Jones, J. P. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors J. Med. Chem. 2004, 47, 6768-6776 (Pubitemid 40053765)
27. Ridderstrom, M.; Zamora, I.; Fjellstrom, O.; Andersson, T. B. Analysis of selective regions in the active sites of human cytochromes P450, 2C8, 2C9, 2C18, and 2C19 homology models using GRID/CPCA J. Med. Chem. 2001, 44, 4072-4081 (Pubitemid 33095316)
28. Yao, Y.; Han, W. W.; Zhou, Y. H.; Li, Z. S.; Li, Q.; Chen, X. Y.; Zhong, D. F. The metabolism of CYP2C9 and CYP2C19 for gliclazide by homology modeling and docking study Eur. J. Med. Chem. 2009, 44, 854-861
29. Suzuki, H.; Kneller, M. B.; Haining, R. L.; Trager, W. F.; Rettie, A. E. (+)- N -3-Benzyl-nirvanol and (-)- N -3-Benzyl-phenobarbital: new potent and selective in vitro inhibitors of CYP2C19 Drug Metab. Dispos. 2002, 30, 235-239 (Pubitemid 34175012)
30. Houston, J. B.; Kenworthy, K. E.; Galetin, A. Typical and Atypical Enzyme Kinetics. In Drug Metabolizing Enzymes: Cytochrome P450 and Other Enzymes in Drug Discovery and Development; Lee, J. S.; Obach, R. S.; Fisher, M. B., Eds.; Marcel Dekker: New York, 2003; pp 211-254.
31. Sutton, D.; Butler, A. M.; Nadin, L.; Murray, M. Role of CYP3A4 in human hepatic diltiazem N -demethylation: inhibition of CYP3A4 activity by oxidized diltiazem metabolites J. Pharmacol. Exp. Ther. 1997, 282, 294-300 (Pubitemid 27425554)
32. Fukushima, Y.; Ushimaru, M.; Takahara, S. On the error of the dixon plot for estimating the inhibition constant between enzyme and inhibitor Biochem. Mol. Biol. Ed. 2002, 30, 90-92 (Pubitemid 44138771)
33. Carter, C. M.; Leighton-Davies, J. R.; Charlton, S. J. Miniaturized receptor binding assays: complications arising from ligand depletion J. Biomol. Screening 2007, 12, 255-266 (Pubitemid 46364429)
34. Lewis, D. F.; Lake, B. G.; Ito, Y.; Dickins, M. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes J. Enzyme Inhib. Med. Chem. 2006, 21, 385-389 (Pubitemid 44355787)
35. Suzuki, H.; Kneller, M. B.; Rock, D. A.; Jones, J. P.; Trager, W. F.; Rettie, A. E. Active-site characteristics of CYP2C19 and CYP2C9 probed with hydantoin and barbiturate inhibitors Arch. Biochem. Biophys. 2004, 429, 1-15 (Pubitemid 39013377)
36. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three and four dimensional-quantitative structure-activity relationship (3D/4D-QSAR) analyses of CYP2D6 inhibitors Pharmacogenetics 1999, 9, 477-489 (Pubitemid 29419566)
37. Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J. S.; Ring, B. J.; Wikel, J. H.; Wrighton, S. A. Three- and four-dimensional quantitative structure-activity relationship analyses of cytochrome P-450 3A4 inhibitors J. Pharmacol. Exp. Ther. 1999, 290, 429-438 (Pubitemid 29302353)
38. Ekins, S.; de Groot, M. J.; Jones, J. P. Pharmacophore and three-dimensional quantitative structure-activity relationship methods for modeling cytochrome p450 active sites Drug Metab. Dispos. 2001, 29, 936-944 (Pubitemid 32605906)
39. Sciabola, S.; Morao, I.; de Groot, M. J. Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability J. Chem. Inf. Model. 2007, 47, 76-84 (Pubitemid 46225562)
40. Rowland, P.; Blaney, F. E.; Smyth, M. G.; Jones, J. J.; Leydon, V. R.; Oxbrow, A. K.; Lewis, C. J.; Tennant, M. G.; Modi, S.; Eggleston, D. S.; Chenery, R. J.; Bridges, A. M. Crystal structure of human cytochrome P450 2D6 J. Biol. Chem. 2006, 281, 7614-7622 (Pubitemid 43847532)
41. Schoch, G. A.; Yano, J. K.; Wester, M. R.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. Structure of human microsomal cytochrome P450 2C8. Evidence for a peripheral fatty acid binding site J. Biol. Chem. 2004, 279, 9497-9503 (Pubitemid 38296017)
42. Wester, M. R.; Yano, J. K.; Schoch, G. A.; Yang, C.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-A resolution J. Biol. Chem. 2004, 279, 35630-35637 (Pubitemid 39100565)
43. Williams, P. A.; Cosme, J.; Ward, A.; Angove, H. C.; Matak Vinkovic, D.; Jhoti, H. Crystal structure of human cytochrome P450 2C9 with bound warfarin Nature 2003, 424, 464-468 (Pubitemid 36917499)
44. Yano, J. K.; Wester, M. R.; Schoch, G. A.; Griffin, K. J.; Stout, C. D.; Johnson, E. F. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05-A resolution J. Biol. Chem. 2004, 279, 38091-38094 (Pubitemid 39295952)